Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...

Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...

Novartis’ blood cancer sculpture tour has reached a new destination. The Swiss drugmaker, which put the sculptures on show in London one year ago, is marking this year’s Blood Cancer Awareness ...

Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the cholesterol-lowering drug. Early Wednesday, the company touted phase 3 ...

Novartis NVS announced positive data on the cholesterol drug Leqvio (inclisiran) from the late-stage V-MONO study. Leqvio is ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...

Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Siemens Healthineers has agreed to buy part of a Novartis business that specialises in producing ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based independent, discovery-stage biotech company. The collaboration has resulted in $150m Series A ...